EFFECTS OF APELIN ON THE CARDIOVASCULAR SYSTEM by Folino, Anna et al.
This is an author version of the contribution published on:
Folino A, Montarolo PG, Samaja M, Rastaldo R
EFFECTS OF APELIN ON THE CARDIOVASCULAR SYSTEM
HEART FAILURE REVIEWS (9999)
DOI: 10.1007/s10741-015-9475-x
The definitive version is available at:
http://link.springer.com/content/pdf/10.1007/s10741-015-9475-x
 1 
 
Effects of apelin on the cardiovascular system 
 
Anna Folino
1
, Pier Giorgio Montarolo
1
, Michele Samaja
2
, Raffaella Rastaldo
3 
 
1
Department of Neuroscience, University of Turin, C.so Raffaello 30, I – 10125 Torino, Italy 
2
Department of Health Science, University of Milan – San Paolo, via di Rudinì 8, I - 20142 Milano, Italy 
3
Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, I – 10043 
Orbassano, Italy 
 
 
 
 
Corresponding author: 
Raffaella Rastaldo, PhD 
Department of Clinical and Biological Sciences 
University of Turin 
Regione Gonzole 10, 10043 Orbassano (TO) - Italy 
e-mail: raffaella.rastaldo@unito.it 
Phone number: +39 011 6705426 
Fax number: +39 011 9038639 
 
 
 
Abstract 
Apelin is an endogenous peptide acting on the APJ receptor. It consists of several isoforms characterised by 
different numbers of aminoacids. The number of aminoacids in the active isoforms range from 36 to 12. Apelin-
13 and, to a lesser extent, apelin-36 are  considered the most active isoforms with the greatest activity on the 
cardiovascular homeostasis. The effects normally exerted by the basal level of endogenous apelin, can be 
enhanced not only by its up-regulation, but may also by its exogenous administration. 
The present review considers the effects of apelin on various aspects of the cardiovascular function, such as 
cardiac development, vasomotor tone, angiogenesis, myocardial inotropy in healthy and failing hearts as well as 
the prevention of ischemia-reperfusion injury, cardiac fibrosis and remodeling. Also the biphasic changes of 
apelin level during the evolution of heart failure are considered. Although the positive inotropic effect exerted by 
apelin in normal and failing hearts would suggest the use of this peptide in the treatment of heart failure, the 
limited duration and extent of its effect do not support this possibility, unless a long lasting (6 hours) infusion is 
performed to overcome the limit of its short life. However, although the data on the characteristics of the 
inotropic activity do not provide a strong support for the treatment of active heart failure, apelin may be used in 
the prevention of heart failure because of its activity in limiting the consequences of myocardial ischemia such as 
infarct size and cardiac remodeling. 
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The apelin/APJ system 
Apelin 
In 1998 Tatemoto et al. discovered the endogenous peptide capable of binding the G protein-coupled receptor 
(GPCR) APJ [1,2], which at that time was considered an orphan receptor becaue its ligand was unknown. The 
just discovered ligand was called, apelin e.g APj Endogenous LIgaNd. Apelin is expressed in hearts, lungs, 
kidneys, liver, adipose tissue, gastrointestinal tract, brain, adrenal glands, endothelium, and human plasma. 
The gene of apelin is located on chromosome X [3] and encodes a 77 aminoacid sequence called pre-pro-apelin 
[4]. Upon cleavage by a family of endopeptidases, pre-pro-apelin generates several C-terminal fragments of 
various size, which are classified on the basis of the number of aminoacids. The active isoforms range from 36 to 
12 aminoacids. As fragments shorter than 12 aminoacids are biologically inactive, it appears evident that the C-
terminal 12 aminoacids are essential for receptor binding, whereas the N-terminal sequence modulates the 
interaction with the receptor [5]. 
At present it is recognized that, although different isoforms display similar functions, active isoforms differ in 
tissue distribution, potency and receptor binding affinity [6]. Apelin-13 and, to a lesser extent, apelin-36 have 
been considered the most active isoforms with the greatest activity on the cardiovascular apparatus [7,4]. 
Recently it has been demonstrated that, the predominant isoforms in the heart are apelin-13 and its post-
transcriptionally modified form, pyroglutamyl apelin-13 ((pyr)apelin-13), which is obtained from apelin-13 by 
enzymatic conversion of the N-terminal glutamate residue into pyroglutamate, while apelin-36 is predominant in 
lung, testis and uterus [6,8]. 
Immunocytochemistry analysis of human hearts revealed that apelin is expressed in cardiomyocytes and in the 
vascular and endocardial endothelium [9,10]. Sartans are a group of hypotensive drugs reported to increase the 
expression of apelin [11]. 
The heart, especially atria, and adipose tissue are the predominant sources of plasma apelin in humans [12,8,6]. 
Apelin-17 and (pyr)apelin-13 have been considered the major isoforms present in human and rat plasma [13,14]. 
A large variability in plasma apelin concentration has been attributed to low specificity of the analysis 
procedures [6]. Recently, mass spectrometry analysis revealed that (pyr)apelin-13 is the major isoform present in 
healthy human plasma, with concentrations ranging 7.7-23.3 pg/ml [6].  
Plasma half-life of apelin-13 and apelin-36 does not exceed 8 min [15]. The instability of apelin in plasma is 
attributed to its rapid degradation by endogenous circulating proteases [6]. Among the various isoforms, 
(pyr)apelin-13 is the most stable, perhaps because its cleavage is protected by the pyroglutamic acid residue 
located at the N-terminal [6]. 
 
The APJ receptor 
The gene of the apelin receptor, APJ, was discovered before its ligand in 1993 and was mapped to chromosome 
11 [1]. APJ is a 377 aminoacid Gi protein-coupled receptor with a 7 transmembrane domain, which was cloned 
from genomic human DNA [1]. The aminoacid sequences of APJ are well conserved in rats and humans [16]. 
Unlike its ligand, APJ occurs not only in human cardiomyocytes and endothelial cells, but also in vascular 
smooth muscle cells (VSMCs) [9]. At the subcellular level, APJ is localized in the T tubules and intercalated 
discs [17]. 
The availability of mice lacking either the ligand or the receptor helps to study the effects of alterations of the 
endogenous apelin-APJ signaling system. While apelin-deficient mice are viable, fertile and show normal 
development, APJ-deficient mice display cardiovascular development defects, suggesting the possibility of 
undiscovered APJ ligands or ligand-independent effects of APJ [18]. An example of such APJ ligand is the 
ELABELA hormone, which is involved in heart development [19,20] while a ligand-independent effect might 
consist in the initiation of cardiac hypertrophy in response to stretch [21]. 
 
General activity of the apelin-APJ system on cardiovascular homeostasis 
Since the early studies on its effects on cardiovascular activity, the acute administration of apelin has been 
reported to reduce the vasomotor tone with increases in heart rate and myocardial contractility with a trend 
towards an increase in preload recruitable stroke work [22-24]. Apelin-induced vasodilation leads to a reduction 
of mean filling pressure, which in turn causes a decrease of preload and afterload. The acute administration of 
apelin may affect the left ventricular performance in one of the following ways: a) reduction of blood pressure, 
stroke volume and cardiac output at unchanged dP/dT despite increased contractility and heart rate [24], or b) a 
significant increase in stroke volume, Pmax and dP/dT [25]. Moreover, the vasodilatation-dependent reduction of 
afterload can result in a reduction of cardiac work with increased cardiac efficiency. 
When apelin was infused chronically over two weeks, the changes in blood pressure and heart rate observed with 
acute administration did not occur, whereas the increase in contractility led to increased stroke volume and 
cardiac output [24]. The occurrence of myocardial hypertrophy was not induced by neither type of apelin 
administration. 
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Apelin/APJ system vs renin-angiotensin system (RAS) 
Note-worthy the aminoacidic compositions of pre-pro-apelin and APJ are similar to those of angiotensin (Ang) II 
and angiotensin II type 1 receptor (AT1R) respectively [3,1,2]. Although APJ shares a 40-50% identity with 
AT1R in the hydrophobic transmembrane region [1,2], the downstream effect of the two receptors is different. 
Ang II and apelin do not bind to APJ and AT1R respectively [1,2]. 
Angiotensin II is implicated in various cardiovascular diseases [26,27]. The apelin/APJ system acts as a counter-
regulator of the renin-angiotensin system (RAS), in which a central role is played by Ang II. Two signalling 
mechanisms are involved in this antagonism: 1) the interaction between AT1 and APJ modulates the function of 
these receptors [28], and 2) the negative regulation of RAS by angiotensin-converting enzyme 2 (ACE2), a 
homologue of angiotensin converting enzyme (ACE) [29,30]. [24,25].  
AT1Rs mediate major cardiovascular effects of Ang II, as induction of hypertension, myocardial hypertrophy 
and fibrosis. The binding of Ang II to its receptors is known to result in increased vasopressin secretion with 
relevant unwanted effects on the cardiovascular system [31]. Usually APJ and AT1R are co-expressed in various 
cardiovascular tissues [28]. Due to their co-expression, the two GPCRs may form an heterodimer which can be 
enhanced by apelin [32,28]. Apelin-13 binding to APJ forces allosteric formation of a heterodimer composed by 
APJ and AT1R in a dose-dependent manner. Upon formation of this heterodimer, the AT1R affinity for Ang II 
decreases markedly, thereby attenuating RAS. Interestingly, the reverse is not true, and AT1R binding to Ang II 
does not suppress the apelin-APJ axis. As a note of caution, the two techniques that have been used to assess this 
reciprocal effect, bioluminescence resonance energy transfer (BRET) and competitive binding assay, did not 
provide exactly convergent results, and this important point needs be further investigated by alternative, 
independent approaches [28]. By contrast, it has been proposed that inactivated APJ can form heterodimers with 
AT1 which suppresses RAS signalling. This inhibitory effect is reduced by the binding of apelin to APJ [33]. In 
addition to the modulation on AT1R signalling, apelin counteracts RAS by up-regulating ACE2 expression via 
APJ (Fig. 1). Unlike ACE, ACE2 is a negative regulator of RAS because it is responsible for the conversion of 
Ang II to Ang 1-7. The importance of apelin in ACE2 activation results from the observation that the latter is 
downregulated in apelin-deficient mice [30]. However, treatment with Ang 1-7 limits myocardial dysfunction, 
hypertrophy and fibrosis [30,34], as well as endothelial dysfunction [35]. Thus, it was thought that the axis 
apelin-ACE2-Ang 1-7 represents a signalling protective pathway and that angiotensin 1-7 does not simply 
indicate Ang II removal, but it also displays a therapeutic effect via its own G-protein coupled receptor, Mas, 
associated with cardiac protective responses [30]. 
ACE2 counteracts RAS also by transforming Ang I into Ang 1-9 by the hydrolysis of the carboxy terminal 
leucine [36,37] (Fig. 1). In turn, Ang 1-9 can be converted to Ang 1-7 by ACE [36]. Angiotensin 1-9 exerts 
beneficial effects on the heart, which consist in reduction of blood pressure, improvement of endothelial function 
and limitation of hypertrophy and fibrosis [38]. It has been suggested that these beneficial effects of Ang 1-9 can 
be achieved via angiotensin II type 2 receptor (AT2R), independently of its conversion to Ang 1-7 [38,39]. 
In addition to the favorable activity on cardiac dysfunction, ACE2 was reported to play a role in the hydrolysis 
of a large number of peptides, including apelin-13 and apelin-36, which are thus degraded to ineffective forms 
[40]. So far, ACE2 has been considered the only enzyme able to cleave the C-terminal residue [40]. However, 
plasma apelin instability has been attributed to its rapid degradation carried out by endogenous circulating 
proteases [6]. 
The antagonism of apelin towards RAS indicates that the former displays an important protective effect against 
cardiac remodelling after myocardial infarction (MI). As it will be discussed later in the present review, the 
treatment with apelin immediately after an ischemic insult can attenuate the injury during early reperfusion [41]. 
Thus, the fact that apelin can limit the immediate and delayed consequences of myocardial ischemia underscores 
its possible role the treatment of coronary artery disease. 
 
Regulation of cardiovascular development and repair 
The involvement of apelin in cardiac development was first identified in the frog [42]. Later on the effect of 
apelin on the differentiation of embryonic stem cells (ESCs) along cardiac lineage was studied in mice and 
humans [43]. More than one half of APJ-null mouse embryos die in utero due to cardiovascular developmental 
defects that range from impaired maturation of yolk sac and embryo vasculature to aberrantly formed right 
ventricles and defective atrio-ventricular cushion formation [44].It was also observed that apelin, if combined 
with mesodermal differentiation factors, not only increases the percentage of contractile embryonic bodies 
derived from ESCs, but also up-regulates various specific markers of differentiation into cardiomyocytes [43]. 
Apelin is also required for normal vascular development. In frogs and mice, APJ expression was detected in the 
endothelium of primary blood vessels and newly forming hearts [45-48]. Moreover during angiogenesis apelin is 
involved in the adaptation of blood vessel size to the tissue demand for oxygen and nutrients in mouse embryos. 
In mice, the formation of retinal vessels during the foetal period and the first two postnatal weeks is 
characterized by a transient up-regulation of apelin/APJ mRNAs in retinal endothelial cells [49,45,50]. This 
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intervention of the apelin/APJ system was confirmed in apelin-null mice, in which the impairment of retinal 
vascularization in the early postnatal period was detected [51]. 
In vitro studies confirmed the role of apelin in vascular development. Apelin promotes proliferation, migration 
and capillary-like formation of retinal endothelial RF/6A cell line with high expression of apelin and APJ 
transcripts [51]. Identical effects were also produced by apelin-13 in myocardial microvascular endothelial 
cells[52]. 
In addition to cardiovascular development, apelin contributes to the post-ischemic vascular regeneration. In 
mouse ischemic hind limbs, transgenic apelin overexpression together, with vascular endothelial growth factor 
(VEGF), promotes the development of relatively large non-leaky vessels. This does not necessarily mean that a 
synergy between apelin and VEGF is required for any apelin activity, because this peptide is known to prevent 
the pro-oedemigenic hyper-permeability by inhibiting VEGF effect [53]. On the other hand, a reduction in 
capillary density and vessel integrity was observed in the heart of apelin-knockout mice after MI [54]. 
 
Molecular mechanisms. Myocyte enhancer factor 2 (MEF2) plays a role in cardiac development [55,56] 
and activated by G13 protein [44]. While in mice apelin administration or APJ overexpression increase class II 
histone deacetylases (HDAC) phosphorylation and translocation from nucleus to cytoplasm, in APJ-null animals 
not only the response is abrogated, but the phosphorylation of HDAC is reduced even in baseline conditions. The 
response is also abrogated in human umbilical vein endothelial cell (HUVEC) by knockdown of G13 protein 
[44]. Taken together, these data indicate that the apelin/APJ system regulates cardiac development via a G13-
HDAC-MEF2 cascade. In zebrafish a role in cardiac development has also been attributed to ELABELA, the 
newly discovered hormone acting as a second ligand of APJ receptors [19,20]. 
Since apelin induces endothelial nitric oxide synthase (eNOS) phosphorylation in endothelial cells and nitric 
oxide (NO) participates to the process of angiogenesis [57,58], the role of apelin in vessel formation is expected 
to be mediated by NO. 
It was observed that apelin stimulates angiogenesis in myocardial microvascular endothelial cells via Thr-172 
phosphorylation of AMP-activated protein kinase (AMPK) and via Ser-1179 phosphorylation of eNOS [52]. The 
pro-angiogenic effect was abolished by compound C, inhibitor of AMPK, and LY294002, inhibitor of 
phosphoinositide 3-kinase (PI3K), indicating that apelin promotes angiogenesis through the AMPK and 
Akt/eNOS signaling pathways [52]. Interestingly, apelin induces proliferation in HUVEC only after the up-
regulation of APJ level by VEGF [59]. However, the pro-angiogenic effect of apelin is independent of growth 
factors [45,46]. 
 
Vasomotor tone 
Earlier studies on the cardiovascular activity of apelin revealed its vasodilator and hypotensive effects 
[3,2,60,15]. Initially, the intravenous injection of apelin in the rat at the dose of 1-2 g/300 g reduced systolic 
and diastolic blood pressure by 10-13% [3]. In another study in the rat, doses of 10 nmol/kg of apelin-12, apelin-
13 and apelin-36 given separately decreased arterial blood pressure by 26, 11 and 5 mmHg, respectively, i.e. 
inversely proportional to the molecular weight of the administered compounds [2]. In the rat, the hypotensive 
effect lasted only a few minutes (2 –3 min) [3,22]. In APJ-deficient mice, basal blood pressure was found to be 
equivalent to that of wild-type mice [60] suggesting, the presence of endogenous apelin plays a poor, if any, role 
in the regulation of basal blood pressure. Exogenous apelin, which transiently reduced blood pressure not only in 
wild type mice, but also in spontaneously hypertensive rats, was ineffective in APJ-deficient mice [60], so that 
the role of APJ in the hypotensive response was underlined. 
Hypotension is responsible for a reduction of the baroreceptor stimulation with decrease of the vagal and 
increase of the sympathetic tones. Tachycardia is a result of these changes in the autonomic activity. In the rat, 
blood pressure reduction is accompanied by a transient (3 - 4 min) increase in heart rate [3]. Such increase has 
been attributed to enhanced sympathetic discharge rather than to reduced vagal tone, which is low in this species. 
In fact, apelin injection was followed by a decrease in both arterial and venous filling pressures without changes 
in heart rate, if the sympathetic ganglia had previously been blocked with mecamylamine [23]. The reduction in 
the overall vascular filling pressure shows that apelin-induced vasodilatation is almost simultaneously extended 
to systemic arteries and veins. However, there is a limit to homogeneous distribution of the vasodilatation 
throughout the entire vascular system. In fact, intravenous bolus injections of apelin in the dog reduces pressure 
in the systemic circulation but not in the pulmonary vascular bed [61]. Hypotension is not the unique response to 
the administration of apelin in vivo. Intravenous injections of 20 and 50 nmol of (pyr)apelin-13 induces dose-
dependent increases in arterial pressure and heart rate in conscious rats [62]. 
The presence of endothelium seems to be necessary for the vasodilator effect of apelin. In fact, in human 
mammary arteries and saphenous veins, apelin reverses its effect into vasoconstriction after removal of the 
endothelium [63]. This latter effect can contribute to the hypertension observed in endothelial dysfunction 
[64,65]. However, the absence of vasoconstriction when the denuded rat portal vein was treated with the peptide 
is intriguing [66]. The discrepancy between the behaviors of portal and saphenous veins may be attributed to 
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differences in type of vessels and in species. Due to the dysfunctional endothelium and the marked increase of 
apelin in their plaques, the human isolated atherosclerotic coronary arteries easily undergo vasoconstriction [67]. 
 
Molecular mechanisms. The hypotensive effect of apelin is mediated by endothelium-derived NO. It was 
not observed in mice [60] and humans [15] after eNOS inhibition or in mice when it was injected in APJ-
deficient animals [60]. These findings confirm the intervention of APJ in the phosphorylation of eNOS and 
production of NO, the latter exerting its well known relaxing effect on the vascular musculature. In brief, after 
binding to APJ on endothelial cells, apelin induces phosphorylation of eNOS via PI3K/Akt activation [68]. The 
endothelium-derived NO diffuses into the VSMCs where it displays its well known vasodilator effect via cyclic 
guanosine monophosphate (cGMP)-protein kinase G (PKG) pathway. The consequent increase in cGMP level 
activates PKG which induces the re-uptake of calcium by the sarcoplasmic reticulum (SR) via 
sarco/endoplasmatic reticulum calcium ATPase (SERCA) activation. PKG also favors dephosphorylation of 
myosin light chains which is responsible for a reduction in number of the cross bridges [69-71]. 
In the absence of a functional endothelium, apelin binds to APJ of VSMCs causing their contraction. The 
pathway leading to apelin-induced constriction of denuded vessels was studied in rat VSMCs and in isolated 
thoracic aorta after endothelium removal [72]. The binding of apelin to APJ of VSMCs causes phospholipase C 
(PLC) activation with production of inositol 1,4,5 phosphate (IP3) and diacylglycerol (DAG). These mediators 
lead to contraction via an increase in intracellular Ca
2+
 concentration and a phosphorylation of myosin light 
chains (MLC) [72]. 
The increase in cellular calcium level is attributed to the opening of IP3 receptor-channels (IP3R) of SR and then 
to Ca
2+
-induced Ca
2+ 
release from ryanodine receptor-channels (RyR) [69]. Also DAG contributes to the increase 
Ca
2+
 level via protein kinase C (PKC) mediated activation of sarcolemmal Na
+
/H
+
 (NHE) and reverse mode 
Na
+
/Ca
2+ 
(NCH) exchangers [69,72]. As it was seen in VSMCs obtained from isolated rat middle cerebral 
arteries, Ca
2+
 concentration may also increase in response to an apelin-induced inhibition of Ca
2+-
activated K
+
 
channels and the consequent increase in the activity of voltage-dependent L-type Ca
2+ 
channels [73]. Finally, 
apelin also inhibits of MLC-phosphatase activity thus inducing a further increase in the phosphorylation of MLC 
[72]. 
 
Inotropic effect 
Apelin is reported to potentiate myocardial inotropy in isolated preparations and intact animals 
[74,24,8,25,17,75,41,69]. For this reason it has been suggested as a tool for the treatment of heart failure (HF) 
[76,70,24,67,77,78]. However, the results of various investigations arise some doubts about this proposal. 
In isolated perfused rat hearts, infusion of apelin-16 produced a progressive dose-dependent (from 1 pM to 10 
nM) increase in developed tension which reached its peak (69%) in 24 min [74]. On the contrary, in similar rat 
heart preparations, a 20 min apelin-13 infusion (500 nM) produced an immediate increase by about 18% in 
developed pressure, which was back to the control 3 min later only [41]. These data are consisted with what 
observed in trabeculae, where apelin-12 induced a transient (1 - 2 min) increase in developed force by about 
7,4% [79]. A short lasting inotropic effect was also seen in isolated adult rat cardiomyocytes, where the 
sarcomere shortening increased for 1 – 2 min only in response to apelin-16 superfusion (1-10 nM) and returned 
to the control before the superfusion was discontinued [17]. 
The different duration of the effect does not seem to be depend on the different isoforms, because (pyr)apelin-13, 
apelin-13 and apelin-36 show comparable potency and efficacy in inducing positive inotropic effect [8,75]. On 
the other hand the importance of different procedures of contractility assessment cannot be disregarded. 
The inotropic effect carried out by apelin is not always accompanied by similar haemodynamic effects. In 
anesthetized mice, increases in contractility were observed, either when 100 nM apelin was infused acutely via 
the internal jugular vein at 5 μl/min for 20 min, or when apelin was infused chronically at 2 mg/kg/day with a 
subcutaneous scruff minipump and hemodynamic measurements were performed after 7 and 14 days of 
treatment [24]. The inotropic effect was revealed by the changes in the slope and intercept of the end-systolic 
pressure-volume relationship after apelin administration. Interestingly, in these animals the acute apelin 
administration was not followed by increases in stroke volume, cardiac output and systolic pressure, i.e by the 
changes that one would expect because of the enhanced contractility [24]. The apparent contradiction between 
increased contractility and unchanged stroke volume and systolic pressure may be attributed to decreases in 
preload resulting from apelin-induced venous dilatation. It cannot be excluded that, in the absence of anesthesia 
which impairs the sympathetic tone, vasodilatation would have been replaced by vasoconstriction, paralleled by 
an increase in pressure, as reported by Kagiyama and his co-workers [62]. It is evident that the uncertainty of the 
hemodynamic changes compromises the possibility to treat heart failure with apelin.  
Unlike what obtained with acute administration, mice heart showed significant increases in cardiac output and 
circumferential shortening after 14 days of apelin chronic administration [24]. In spite of the long treatment with 
apelin, no cardiac hypertrophy was observed. These results of the chronic administration suggested the 
possibility of a therapeutic use of the peptide in the failing heart, which in fact was seen to exhibit improvements 
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of contractility in response to apelin infusion (0.01 g/min for 20 min) performed 6 weeks after ligation of the 
left descending coronary artery [25]. It may be argued that the reduction in filling pressure after acute 
administration was curtailed with time in chronically repeated infusions [74]. This hypothesis seems to be 
confirmed by experiments performed ex vivo or in vitro, i.e. in the absence of any variable distension force. In 
these experiments, force development increased after apelin in trabeculae of the failing right ventricle of the rat 
[79] and in cardiomyocytes from chronic post-ischemic rat heart [17]. It is note-worthy that in both preparations 
the inotropic effect was stronger in failing than in healthy hearts, so that various authors support the hypothesis 
that apelin should contribute to the treatment of patients with heart failure . 
 
Molecular mechanisms. Usually a positive inotropic effect is attributed to an increase in intracellular 
calcium level. Activations of L type Ca
2+
 current or of NHE and reverse mode NCE exchangers are considered 
responsible for such an increase [80-83,74]. However, the mode of action of apelin on myocardial calcium 
movement is a matter of debate. 
Szokodi and his coworkers demonstrated that apelin does not modulate L-type Ca
2+
 current in isolated adult rat 
cardiomyocytes. Since in isolated rat hearts the separated inhibition of PLC, PKC, NHE and reverse mode NCE 
limited the increase in myocardial inotropy, they attributed the improvement of contractility to the activation of 
these factors [74]. Thus, they proposed that DAG, obtained from phosphoinositide hydrolysis by PLC, is 
responsible for the activation of NHE via PKC. The resulting increases in intracellular Na
+
 concentration lead to 
an increase in intracellular Ca
2+
 level via the reverse mode of NCE [74] (Fig. 2). The involvement of NHE and 
NCE in the inotropic activity of apelin has been confirmed by Wang et al. [84] who also demonstrated that 
apelin increases the SERCA-regulated re-uptake of Ca
2+
 into the SR in a PKC-dependent manner, thus adding 
the lusitropic effect to the inotropic one. Independently of the way by which apelin induces the entrance of Ca
2+ 
into the cell, it can be argued that the initial increase in calcium level can also take place via the Ca
2+
-induced 
Ca
2+
 release through the opening of RyR of SR. Moreover, a release of Ca
2+
 from SR also results from the 
activation of IP3R by IP3, which results from phosphoinositide hydrolysis [69]. 
Since the apelin-induced increase in contractility was not totally abolished by the blockade of the two 
exchangers, the authors suggested the possibility that an increase in troponin C affinity for Ca
2+
 or in the cyclin 
rate of actomyosin cross-bridges could contribute to the inotropic effect [74] (Fig. 3). 
An increased myofilament sensitivity to Ca2+ in the absence of any change in Ca
2+
 level was later attributed to 
the alkalinization of sarcoplasm following the loss of H
+
 because of an increased NHE activity. This hypothesis 
found support when measurements of the sarcomere shortening in isolated cardiomyocytes showed that the 
positive inotropic effect was not accompanied by any increase in Ca
2+
 concentration [17,85]. 
Recently, Perjés et al. [75] demonstrated that the raises in myofilament Ca
2+
 sensitivity and cross-bridge kinetics 
is due to the phosphorylation of regulatory myosin light chain (RMLC) via myosin light chain kinase (MLCK) 
(Fig. 3). The inotropic response was suppressed by the inhibition of the parallel PKCε and mitogen-activated 
protein kinase kinase (MEK) – extracellular signal-regulated kinases 1/2 (ERK 1/2) pathways. Although cardiac 
MLCK and RMLC have been proposed as potential downstream targets of PKC , the real cascade leading to 
MLCK is still elusive. 
Finally, although low concentrations of nitric oxide can increase the force of contraction [86,87], NOS inhibition 
has not been seen to alter the apelin-induced increase in contractility [74]. 
 
Apelin in heart failure 
In HF, apelin and AJP expressions vary in a biphasic mode, i.e they are unchanged or upregulated if HF is 
compensated, while they are downregulated if HF is decompensated [77,70]. In particular, in the rat the elevation 
of apelin gene expression in vivo was seen to take place within 24 hours after MI, when an increased apelin 
release contributes to compensate the sudden HF [76]. Consistently, apelin deficiency in humans worsens the 
damage of ischemia-reperfusion (I/R), included extension of infarct size, related inflammation and mortality 
[54]. Taken together, these data indicate that, whereas apelin/APJ expression increases in response to 
pathological stimuli, its deficiency worsens the effects of these stimuli. 
Apelin production falls when HF becomes chronic or more severe [76]. An example of this fall is the reduction 
of the myocardial level of apelin observed in the dog with an advanced HF induced with microembolization of a 
coronary artery [78]. The biphasic changes in apelin release are in line with the general opinion that in the early 
stages of HF, factors activating the force of contraction, as e.g. enhanced sympathetic activity, can improve the 
cardiac function, while later they become progressively maladaptive and lead to a worsening of the cardiac 
conditions. 
In apparent contrast with the above results, in humans it was seen that left ventricular apelin mRNA did not 
decrease, but increased in the last stage of chronic HF secondary to coronary disease or idiopathic dilated 
cardiomyopathy [12]. Such increase was not observed in atria, which are the main source of cardiac-generated 
apelin in normal conditions and was accompanied by reduction in ventricular APJ mRNA level. Moreover, in 
spite of the elevated ventricular apelin expression, apelin-like immunoreactivity was remarkably reduced in 
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plasma. Thus, the overall scenario is in favor of a reduced rather than an increased apelin activity. In the absence 
of any change in apelin level, a reduction in density of APJ receptors was observed in another investigation on 
chronically failing human left ventricles [67]. Although the authors argued that this reduction might contribute to 
the contractile dysfunction, it may represent a protective limitation of the cardiac responsiveness to the inotropic 
effect of apelin. 
A decreased of apelin content in plasma, as well as in atrial and ventricular myocardium, may be obtained in rats 
with heart failure produced with repeated high doses of isoproterenol [88]. In this model, the heart failure is 
significantly improved by apelin administration.  
 
Molecular mechanisms. Myocardial ischemia by coronary disease, together with post-infarction 
remodelling, is considered the most frequent cause of HF [89,54]. The increase in apelin expression in response 
to acute hypoxia is mediated by hypoxia-inducible factor-1 (HIF-1) [76]. In fact, hypoxia has been found to be 
responsible for HIF-1 stabilization and nuclear translocation resulting in a 27-fold increase in apelin RNA level 
[76]. It may then be argued that also when a HF is the results of a chronic coronary artery disease, HIF-1 
mediates apelin production during the first phase of the failure. 
The mechanisms of the positive inotropic activity displayed by apelin in HF are considered to be the same that 
improve the contractility of normal hearts, via the intervention of NHE and NCE [17]. Moreover, also the 
antagonizing effect of apelin/APJ system on RAS might be a support to the beneficial effect. Conversely, in the 
late phase of failure an increased RAS activation would be responsible for the reduction of apelin expression 
[70]. 
 
Apelin in myocardial protection 
Protection against ischemia-reperfusion injury 
Heart may be protected against I/R injury by ischemic pre- (PreC) or postconditioning (PostC). While PreC is 
performed with brief (2 - 2.5 min) coronary occlusions 5 – 10 min before a heavy ischemic challenge, PostC is 
obtained with even shorter (seconds) occlusions, starting a few seconds after the end of the ischemia. The largest 
part of the reperfusion injury occurs in the first minutes after the end of the ischemia in the correspondence of 
ROS burst [90,91]. Consequently, the first minutes of reperfusion are a good window for the PostC 
interventions. However this is not a strict limit, because sometimes the infarct size may increase for 2-12 hours 
during reperfusion after ischemia in the rat heart [92]. 
In the isolated rat heart, the size of a MI caused by 35 min of occlusion of the left main coronary artery was 
significantly reduced if an 8 M exogenous apelin solution was infused for 20 min starting 5 min before the 
onset of reperfusion [93]. On the contrary, it remained unchanged if the infusion started 5 min before the onset of 
reperfusion and ended before removing the occlusion, suggesting that apelin mimics PostC rather than PreC. The 
hypothesis was confirmed by Rastaldo et al. [41], in Langendorff isolated rat heart preparation perfused with 0.5 
M apelin-13 buffer for 20 min before or after the end of a 30 min global ischemia. While no protection was 
seen when apelin was given before ischemia, significant reductions of infarct size and improvement of post-
ischemic mechanical recovery were obtained when apelin was given at the beginning of reperfusion. It is likely 
that the ineffectiveness of apelin before ischemia is due to its short half life [15] which does not allow the 
peptide to reach the level required for protection at the onset of reperfusion. 
The expression of endogenous apelin mRNA was significantly increased at the end of ischemia and returned to 
control value after 60 min of reperfusion [93]. By contrast, the expression of APJ mRNA was unchanged at the 
end of ischemia [41,93]. These data confirm that apelin mimics PostC rather than PreC and that an endogenous 
production of apelin during ischemia might represent a process of myocardial self-protection. The fact that the 
increased expression of apelin mRNA was no longer present after 60 min of reperfusion is not in contrast with 
this opinion, because it is accepted that usually most of I/R injury takes place during the first minutes after the 
end of ischemia. 
In mouse hearts, a reduction in IS occurred to a greater extent with apelin-13 and to a lesser extent with apelin-
36 [4]. A similar reduction was also seen in mouse in vivo with occlusion of the left descending coronary artery, 
and the administration of apelin-13 an apelin-36 [4]. In this model the administration of apelin-13 resulted in a 
transient initial well evident recovery of mean arterial pressure, which however did not exceed the value 
recorded before the onset of ischemia. Since the effect of apelin on the resistance and capacitance vessels is 
dilatory, the pressure increase should be solely attributed to the increase of cardiac performance. It is intriguing 
that such increase was not observed with apelin-36 [4]. The cardioprotective effect against I/R in in vivo rat 
model was also obtained by apelin-12 administration [94]. 
I/R-induced myocardial dysfunction consists in an increase of left ventricle diastolic pressure (i.e. contracture) 
accompanied by reduction of systolic and developed pressures. In isolated perfused rat hearts, Zeng et al. [95] 
observed that after 40 min of global ischemia and 30 min of reperfusion, the mechanical performance was highly 
ameliorated if 30 pM apelin was infused throughout the entire experimental period. 
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From the above data, apelin protection against I/R injury clearly consists in reduction of the infarct size and 
improvement of the post-ischemic mechanical recovery. However, it remains unclear whether the improved 
mechanical recovery is simply the consequence of the reduction of the infarct size or it is also due to the direct 
inotropic effect of apelin. In Langendorff rat heart preparations [41], the improvement of post-ischemic 
mechanical recovery took the developed pressure back to almost the value recorded before ischemia, where it 
remained throughout the entire period of reperfusion. Since when apelin was infusion before ischemia, only a 
slight and brief increase in developed pressure was obtained [41], the hypothesis that a direct inotropic effect of 
apelin contributed to post-ischemic mechanical recovery must be refused. 
 
Molecular mechanisms. Apelin protects the heart against I/R injury via either a NO-dependent or a NO-
independent pathway, which are both components of the Reperfusion Injury Salvage Kinase (RISK) cascade. 
NO-dependent pathway begins with the activation of PI3K-Akt system which is responsible for the activation of 
eNOS. In fact, in in vivo mice with LAD occlusion, the inhibition of PI3K with LY294002 abolished apelin-
induced reduction of the infarct size [4]. The role of PI3K was confirmed by the observation that the protection 
was accompanied by enhanced Akt phosphorylation in mice isolated hearts during reperfusion after global 
ischemia [96] and in neonatal rat cardiomyocytes during reoxygenation after hypoxia [95]. Moreover, the 
blockade of NOS prevented the protective effect of apelin-13 in the rat [41]. 
In a study no impairment of apelin-induced cardioprotection was observed in isolated rat hearts after inhibition 
of PI3K [93].This finding is consistent with the possibility that apelin leads to myocardial protection also via a 
NO-independent pathway. In fact, phosphorylation of ERK 1/2 and the effect of its blockade [4] suggest that a 
relevant NO-independent cascade elicited by G-protein activation is responsible for the apelin protective activity 
via the downstream regulation of Bax/Bad pro-apoptotic proteins [97]. Both these protective pathways prevent 
the opening of mitochondrial permeability transition pore (mPTP) which is considered the key factor of I/R 
injury. In contrast, no data are available on the role of the Survivor Activating Factor Enhancement (SAFE) 
pathway in apelin-induced myocardial protection.  
 
Protection against apoptosis 
Apoptosis, a complex process of programmed cell death, occurs in all multicellular organisms. Although still 
debated whether apoptosis represents a protective or an aggressive phenotype, it is likely that attenuation of 
apoptosis in organs with low regenerative potential, such as the myocardium, is protective. In I/R injury and in 
dilated cardiomyopathy, apoptosis may also be triggered by the accumulation of unfolded or misfolded proteins 
in the endoplasmic reticulum (ER), or ER stress [98,92]. 
Earlier observations obtained in mouse osteoblastic MC3T3-E1 cells show that apelin suppresses apoptosis 
induced by serum deprivation [99]. Later it was demonstrated that the anti-apoptotic effect of apelin concerns 
olso the cardiovascular system [92,95]. In in vivo rat hearts exposed to 30 min of ischemia followed by 
reperfusion, the activation of ER stress-dependent apoptosis was attenuated by the administration of 1 μg/kg 
apelin [92].Similar results were found in Langendorff isolated hearts of the same spieces. Although in 
reperfusion APJ is over-expressed at both mRNA and protein levels (by 7-fold and 35%) during I/R, pre-
administration of 30 pmol/L apelin reduces apoptosis thereby ameliorating heart function, in conjunction with 
reduced generation of reactive oxygen species [95]. 
Patients with pulmonary artery hypertension have lower levels of plasma apelin and decreased apelin expression 
in pulmonary endothelial cells [100]. These apelin-deficient cells are more prone to undergo apoptosis and to 
promote proliferation of pulmonary arterial smooth muscle cells. On the other side, apelin administration can 
reverse pulmonary artery hypertension in mice that show a reduced production of apelin [101]. Furthermore, 
apelin suppresses serum deprivation-induced apoptosis of human VSMCs [102] and of rat bone marrow-derived 
mesenchymal stem cells [103], the latter bearing great promise for ischemic tissue repair, despite their poor 
viability within ischemic tissues. 
Of interest, the apelin/APJ system has positive effects on the apoptotic potential in organs other than the 
cardiovascular system [104-108], further supporting the beneficial systemic effects of this drug. 
 
Molecular mechanisms. In general, the two main pathways of apoptosis regulation include targeting of 
mitochondria functionality (intrinsic pathway), and external signal transduction via adaptor proteins or increased 
intracellular calcium concentration (extrinsic pathway).  
In the latter pathway, PI3K/Akt stimulation plays a pivotal role in the beneficial activity of apelin against 
apoptosis as demonstrated by its impairment by PI3K inhibitor LY294002 [102,109]. Moreover, in mouse 
osteoblastic MC3T3-E1 cells the suppression of serum deprivation-induced apoptosis by apelin is also mediated 
by the activation of c-Jun N-terminal kinase (JNK) pathway [99]. In the case of mesenchymal stem cells, the 
protection from apoptosis is achieved by apelin via the usual PI3K/Akt signaling pathways coupled to the 
inhibition of the mitogen activated protein kinases (MAPK)/ERK 1/2 pathway [103]. 
 9 
 
In rat hearts, ER stress-dependent apoptosis was attenuated by PI3K/Akt, AMPK and ERK. In particular, using 
specific inhibitors, it was demonstrated that PI3K/Akt and AMPK are reciprocally dependent for their activation 
and exert a stimulating effect on eNOS, while ERK did not show any interaction with the other signals 
suggesting to belong to a NO-independent pathway to apelin-induced protection [92]. It may then be argued that 
NO-dependent and NO-independent pathways concern not only the protection against I/R injury in general, but 
also in the specific outcome that is apoptosis. 
 
Protection against cardiac remodelling 
Cardiac fibrosis and remodelling lead HF to end-stage. The process requires the differentiation of cardiac 
fibroblastS into myofibroblasts and is mediated by transforming growth factor- (TGF-). Experiments were 
performed in vitro and in vivo [110]. In vitro it was demonstrated that pretreatment of mouse fibroblasts with 
apelin prevents TGF- from inducing both the expression of myofibroblast marker -smooth muscle actin (-
SMA) and collagen production [110]. In vivo, it was seen that in mouse remodelling and ventricular dysfunction 
are impaired either if apelin is given before or 2 weeks after aortic banding [110]. 
In high salt loaded Dahl salt-sensitive hypertensive rats, a 7 day intraperitoneal administration of (pyr)apelin-13 
at the dose of 200µg/kg/day suppressed the expression of inflammation factors, such as tumor necrosis factor-α 
and interleukin-1β protein [111], which can induce myocardial fibrosis and remodeling [112]. 
 
Molecular mechanisms. TGF- stimulates the differentiation of fibroblasts into myofibroblasts via the 
intervention of a sphingosine kinase 1 (Sphk 1). Thus, it has been proposed that the reduction of the activity of 
Sphk 1 is the starting point of apelin cascade in protecting the heart against fibrosis and remodelling. Once Sphk 
1 is inhibited, the absence of -SMA expression and of collagen production is consistent with the impossibility 
for fibroblasts to differentiate into myofibroblasts [110]. Moreover, in Dahl salt-sensitive hypertensive rats the 
up-regulation of ACE, AT1R and nuclear factor--B (NF-B) was inhibited by apelin-13 treatment [111]. These 
results confirm the hypothesis that RAS and NF-B can lead to cardiac fibrosis and remodelling [113-115]. 
 
Is apelin a therapeutic tool? 
As the inotropic effect of apelin is well evident in failing hearts, a potential role of exogenous apelin for the 
treatment of HF has been suggested [24,15,29,25,116]. Although based on consolidated opinions including the 
simultaneous reduction of afterload, this point needs careful considerations. 
A limitation to the use of apelin for pharmacological treatment of HF is the short (1 - 2 min) duration of its 
inotropic effect. The short-lasting effect also concerns vasodilatation, i.e. the reduction of afterload which 
otherwise should be expected to ameliorate cardiac efficiency. Thus, effective treatments would require chronic 
administration, consisting in repeated subcutaneous injections or prolonged infusions, because a peptide cannot 
be administered successfully via oral administration. However, the increase in cardiac index that was observed in 
humans with chronic heart failure throughout a six hours infusion of (pyr)apelin-13 suggests that at the moment 
APJ agonism may hold promise to complement the current medical therapies [116]. 
Moreover, in our experiments a modest increase in pressure suggests that apelin is not always one of the 
strongest inotropic compounds as sometimes it has been reported [74,41]. On the other hand, chronic apelin 
administration may be a key factor leading to tumorigenesis [117,118]. Independently of the duration and 
intensity of the effect on contractility, it must be kept in mind that at present the use of inotropic drugs is quite 
limited, because of their poor long term therapeutic effectiveness.  
Rather than contractility, the beneficial effect of apelin mainly concerns myocardial protection against I/R injury, 
post-ischemic remodeling and myocardial fibrosis. The limitation of I/R injury offers the chance to set up a 
pharmacological post-conditioning procedure by intracoronary injection of apelin during post-infarction 
angioplasty. Since I/R may result in a rapid irreversible deterioration of myocardial contractility, apelin 
administration may represent a valid upstream prevention of HF, independently of the short duration of the effect 
of apelin on myocardial contractility. 
Heart failure may be prevented by contrasting myocardial remodeling and fibrosis. The question then arises 
whether this prevention is produced not only by exogenous, but also by endogenous apelin. The production of 
endogenous apelin may be enhanced by sartans, a group of drugs which are used successfully against 
hypertensions [11]. With sartans the risk of an unwanted hypotensive effect must not be disregarded before the 
treatment is undertaken. Studies should be carried on to see whether a well modulated use of these drugs could 
prevent cardiac remodelling, fibrosis and apoptosis by a non-excessive increase of plasma and tissue apelin 
concentration. 
 
Conclusion 
In conclusion, while the chance to treat failing hearts with the inotropic activity of apelin is still doubtful, there is 
the possibility that apelin could curb the onset or progression of a postischemic heart failure. This prevention is 
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the result of the protection against I/R injury, apoptosis, fibrosis and remodelling. As a consequence, the use of 
apelin as exogenous pharmacological intervention appears a promising and worth pursuing preventing tool. 
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Figure captions 
Fig 1 Antagonism between Apelin/APJ system and renin-angiotensin system. ACE angiotensin converting 
enzyme; ACE 2 angiotensin converting enzyme 2; Ang Angiotensin 
 
Fig 2 Apelin-induced increased contractility via calcium-dependent mechanism. PLC phospholipase C; PIP2 
phosphoinositol biphosphate; DAG diacylglycerol; IP3 inositol triphosphate; PKC protein kinase C; NHE 
sodium-hydrogen exchanger; NCE sodium-calcium exchanger; IP3R  inositol triphosphate receptor; RyR 
Ryanodine receptor;  SR sarcoplasmic reticulum 
 
Fig 3 Apelin-induced increased contractility via calcium-independent mechanisms. PLC phospholipase C; PIP2 
phosphoinositol biphosphate; DAG diacylglycerol; IP3 inositol triphosphate; PKC protein kinase C; NHE 
sodium-hydrogen exchanger; MEK 1/2 mitogen-activated protein kinase kinase; ERK 1/2 extracellular signal-
regulated kinases 1/2; MLCK myosin light chain kinase; RMLC regulatory myosin light chain;  
 18 
 
 
 19 
 
 
 20 
 
 
